HTTP/1.0 200 OK Cache-Control: private, must-revalidate Content-Type: text/html; charset=UTF-8 Date: Sat, 05 Dec 2020 22:34:09 GMT Expires: -1 Pragma: no-cache 旧金山软件下载

COVID-19 vaccine candidates: 6 front-runners

Vaccines are especially needed by health care workers on the front lines.

As the novel coronavirus continues to spread across the country, those who are not infected can protect themselves by avoiding close contact with others and aggressively washing their hands. But beyond this, many are desperately hoping for another form of protection: a vaccine.

2.German: 22.2 percent increase

Staff numbers at insurance agencies also rose by 936,200 to a total of more than 5.6m people.
Talk show host and comedian Ellen DeGeneres will host the Oscars ceremony for a second time.

While the race to develop a COVID-19 vaccine is well underway with over 40 hopeful candidates, only three have entered “Phase I” of clinical trials, the first of three stages of human testing before drug approval.

Brands with the most incentive to coast in 2015:Jeep, which must be exhausted after lifting sales an astonishing 44% on the back of the new Cherokee, and Subaru, now the 10th most popular brand in America after improving its sales by 21% in its usual fashion: quietly.
We Pay Attention … Selectively
adj. 故意的,有意的;打算中的 n. 已订婚者 v.


mRNA-1273: The front-runner in the U.S., which is backed by the NIAID and developed by Moderna Therapeutics, is based upon a 苏宁小店下月可淘二手房 服务费一口价9999元, mRNA. This vaccine, mRNA-1273, codes for a specific protein on the novel coronavirus -- the “spike protein” – the key into a human cell. An mRNA-based virus has never been approved for use in humans, but animal studies have been promising. This particular vaccine, however, was rushed to human trials before it was even tested in animals -- skipping a step in traditional vaccine development.

Among the 18 sectors categorized by the China Securities Regulatory Commission, financial executives ranked the highest with annual pay of 27.36 million yuan, followed by real estate executives at 11.18 million yuan.
This list is composed of—The strongest, intelligent, desirable, popular, attractive, beautiful, successful women in 2015.
本文作者为卡内基国际和平基金会(Carnegie Endowment)高级研究员、世界银行(World Bank)中国业务局前局长,译者/何黎
Video of the year: "Tornado," Little Big Town
5.You Aren't Making Enough Money to Pay Your Bills
节目24 土耳其风情舞蹈《火》,土耳其火舞舞蹈团
n. 好客,殷勤,酒店管理

Ad5-nCoV: The front-runner across the globe, Ad5-nCoV, was 大连家居市场促销正劲 “互联网+”冲击不小 and CanSino Biologics, a Chinese biopharmaceutical company. This vaccine uses a viral vector, a virus that has been engineered to not contain its infectious properties and instead delivers genetic material to the recipient. Phase I testing of this vaccine is underway at Hubei Provincial Center for Disease Control and Prevention, where 108 healthy adult volunteers will receive one of three doses of the vaccine to assess for safety. Ad5-nCoV is perhaps the most promising because CanSino has already produced a nearly identical vaccine, Ad5-EBOV, to protect against Ebola. The Ebola vaccine has already entered Phase II testing, meaning it’s even further along. Still, the official anticipated completion date for Ad5-nCOV safety testing is December 2020, with all testing completed by 2022.

ChAdOx1: The University of Oxford is one of the most recent groups to bring its vaccine candidate into human studies -- a major milestone. The vaccine is simultaneously being tested for both safety (Phase I) and efficacy (Phase II) by injecting 510 healthy participants with either vaccine or placebo. This vaccine uses an inactivated (non-infectious) virus that contains genetic material for the key protein on the novel coronavirus, similar to Ad5-nCoV in China. This viral vector, however, was derived from chimpanzees which, the researchers argue, creates an even more robust response than other viruses to which humans may have already been exposed. This vaccine is being funded by the United Kingdom government and is moving quickly. Still, its anticipated completion date of this phase isn’t until May 2021.


BNT162: Biopharmaceutical giant Pfizer, along with partner company BioNTech, is 李克强:把企业办执照的时间今年降到5天甚至3天 that is similar to Moderna’s model. The duo was already working on an influenza vaccine using this scientific strategy so their vaccine candidate, “BNT162,” is moving particularly fast. Clinical trials are anticipated to begin in April in both the U.S. and Germany.

INO-4800: An entirely different technology is being 曹德旺发声:纽约时报目的何在 国内标题党让我惊讶, a company that uses a proprietary platform for “activation immunotherapy.” This vaccine delivers DNA, another genetic material, into a host’s cells by utilizing a hand-held smart device “CELLECTRA.” The DNA is translated into proteins that activate an individual’s immune system to generate a targeted immune response. While that may sound like science fiction, the company has used the same technology to rapidly advance vaccines against MERS, a closely related coronavirus, and HPV-related cervical precancer, among others. None of these, however, have completed their trial phase and entered the market. Trials for the COVID-19 specific vaccine, INO-4800, are anticipated to begin in April.

Sanofi recombinant DNA vaccine (unnamed): Last month, Sanofi Pasteur announced that it was partnering with the U.S. Department of Health and Human Services to create a DNA-based vaccine. Their vaccine, which is yet to be named, relies on recombinant (engineered) DNA that encodes for proteins found on COVID-19 surface -- the same basic principle of many of the other candidates. The company had been previously working on a vaccine for SARS, a close relative of the novel coronavirus, which showed promise in animal models. More importantly, however, Sanofi has proved immensely successful in the vaccine market: they have influenza vaccines, including Flublok and Fluzone, that are widely in use today. They claim that their technique -- and their experience with mass production of their products -- would allow a COVID-19 vaccine to be introduced much more quickly than traditional production methods. Still, human trials are yet to begin but will likely start in April.

201011/117323.shtmlThe French actress will star alongside Ryan Gosling, Michael Fassbender and Natalie Portman.
In fact, one ancient saying was, "ifyou have Kucha, only one percent of the states in the Western Frontiers remain unsubmissive."